Last reviewed · How we verify
CKD-498 dose#2
CKD-498 dose#2 is a SGLT2 inhibitor Small molecule drug developed by Chong Kun Dang Pharmaceutical. It is currently in Phase 2 development for Type 2 diabetes.
CKD-498 dose#2 is a small molecule that targets the SGLT2 receptor.
CKD-498 dose#2 is being studied in a Phase 2 clinical trial for the treatment of Androgenetic Alopecia in female patients. The trial is evaluating the safety and efficacy of CKD-498 in a randomized, double-blind, multi-center, parallel-group design.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CKD-498 dose#2 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
CKD-498 dose#2 works by inhibiting the SGLT2 receptor, which reduces glucose reabsorption in the kidneys and lowers blood glucose levels. This mechanism is similar to other SGLT2 inhibitors, which have been shown to be effective in treating type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
- Increased risk of urinary tract infections
- Dehydration
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-498 dose#2 CI brief — competitive landscape report
- CKD-498 dose#2 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI
Frequently asked questions about CKD-498 dose#2
What is CKD-498 dose#2?
How does CKD-498 dose#2 work?
What is CKD-498 dose#2 used for?
Who makes CKD-498 dose#2?
What drug class is CKD-498 dose#2 in?
What development phase is CKD-498 dose#2 in?
What are the side effects of CKD-498 dose#2?
What does CKD-498 dose#2 target?
Related
- Drug class: All SGLT2 inhibitor drugs
- Target: All drugs targeting SGLT2
- Manufacturer: Chong Kun Dang Pharmaceutical — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing